Comparison of Two Different Induction Doses of Atracurium in Myasthenia Gravis in Patients Undergoing Thymectomy

Alireza Sharifian Attar 1, Reza Jalaeian Taghaddomi 2, Hossein Fattahi Masoum 3, Mohsen Foroughipour 4, Mohammad Reza Hedayati Moghaddam 5, Parisa Mohebbi 6

1Anesthesiologist, Cardio-Thoracic Surgery & Transplant Research Center, Emam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2Anesthesiologist, Anesthesia Department, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3Thoracic Surgeon, Thoracic Surgery Department, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
4Neurologist, Neurology Department, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
5Research Center for HIV/AIDS, HTLV and Viral Hepatitis, Iranian Academic Center for Education, Culture & Research (ACECR), Mashhad Branch, Mashhad, Iran
6Resident of Anesthesiology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

ARTICLE INFO

Article type: Original Article

Article history:
Received: 15 March 2013
Revised: 11 April 2013
Accepted: 29 June 2013

Keyword:
Atracurium
Myasthenia Gravis
Pyridostegmine
Thymectomy

Introduction: Myasthenia gravis is an autoimmune disorder resulting from a decreased number of active acetylcholine receptors at the neuromuscular junction. Thymectomy is one of its current treatments. Due to sensitivity of myasthenic patients to non-depolarizing muscle relaxants and also the interaction of this medication with anti-cholinesterase drugs, determining the dosage of non-depolarizing muscle relaxants for induction of anesthesia is one of the hurdles in thymectomy.

Materials and Methods: Twenty myasthenic patients undergoing transsternal thymectomy were enrolled into the study. They were divided into two groups randomly, and received either 0.25 mg/kg or 0.50 mg/kg of atracurium to facilitate tracheal intubation. Neuromuscular blockade was measured using train of four (TOF) mode of neuromuscular stimulator 15 minutes after administration of atracurium and then each 5 minutes till entered the recovery phase. The time between injection of atracurium and the recovery phase was compared between the two groups.

Results: The two groups were similar with respect to age and gender. The time from the onset of myasthenia gravis to surgery, dosage and duration of pyridostegmine used preoperatively were not significantly different between the two groups. The time from administration of atracurium to recovery phase was not significant between the two groups (P=0.24).

Conclusion: There was no difference between two different doses of atracurium regarding entering the recovery phase, and as the effects of non-depolarizing muscle relaxants are unpredictable in myasthenic patients, we recommend the lower dose to prevent profound skeletal muscle weakness and postoperative complications.

Introduction:
Myasthenia gravis (MG) is a chronic autoimmune disease caused by a decrease
antibodies (1). Three abnormalities are seen at the neuromuscular junction in myasthenic patients: (a) reduction of the number of acetylcholine receptors and the amount of this reduction correlates to the degree of weakness. (b) Unfolding of the postsynaptic membrane or implification of the folding. (c) Increased gap between the nerve terminal and postsynaptic membrane (2). Weakness and rapid exhaustion of voluntary muscles are the hallmark of this disease. Skeletal muscles innervated by cranial nerves (ocular-phryngeal and laryngeal muscles) are especially vulnerable, as reflected by the appearance of ptosis, diplopia and dysphagia, which are often the initial symptoms of the disease (3).

Treatment for MG includes anticholinesterase drugs, thymectomy, immunosupression, and short-term immunotherapy such as plasmapheresis and administration of immunoglobulin (4). Thymectomy is intended to induce remission or at least allow for the doses of immunosuppressive medication to be reduced (5). Anesthetists have a special concern in MG because of its interaction with various anesthetic agents, specially neuromuscular blocking drugs and also the effect of the medications used for treatment of MG (6). The decrease of acetylcholine receptors results in an increased sensitivity to nondepolarizing muscle relaxant. Also drugs that used to treat MG such as pyridostegmine can influence the effect of non-depolarizing muscle relaxant and interfere with these drugs (7). Pyridostegmine, a long-acting acetylcholinesterase inhibitor is the first-line therapy acts by inhibiting synaptic acetylcholinesterase, thus overcoming the deficit in receptor density in patients with MG and reduce the sensitivity of the patients to non-depolarizing muscle relaxants (8). So it seems that the dose of relaxant agents has to be reduced. On the other hand perioperative anticholinesterase treatment will modify the response to reversal agents because of already existing acetylcholinesterase and in some cases recovery of neuromuscular function after the administration of a reversal agent has been reported to be prolonged. Atracurium is an intermediate-acting nondepolarizing relaxant, which undergoes organ-independent degradation in plasma by Hofmann elimination at physiological pH and temperature, as well as by nonspecific ester hydrolysis (9). Is the use of muscle relaxants safe in myasthenic patients? What is the appropriate dose? What is the impact of preoperative use of pyridostigmine on the use of neuromuscular blocking agents intraoperatively. These questions are very important in anesthesia management of myasthenic patients. Optimal management of the myasthenic patients undergoing thymectomy requires: (a) Knowledge of the physiology and relevant pharmacology of myasthenia gravis in order to understand how the clinical manifestations and treatment of the disease affect anesthesia management. (b) Adequate planning, involving close liaison between neurologist, surgeon, anesthetist and intensivist is necessary so that the patient’s neuromuscular function is optimized preoperatively, and postoperative care is organized. (c) Continuous neuromuscular monitoring during anesthesia to manage the changing neuromuscular function that occurs in response to preoperative and intraoperative drug therapy (10). The aim of this study was to compare two different doses of atracurium on muscle relaxation and recovery phase in patient with MG.

Materials and Methods:
Medical Faculty Ethic Committee approval and informed written consent from all patients were obtained. From June 2010 to April 2012, all consecutive patients scheduled for thymectomy because of
Comparison of Two Different Induction Doses

Sharifian A et al

Twenty patients with mean age of 30.2±7.9 and female to male ratio of (65%). The patients were similar with respect to age and gender (Table 1) (p=0.36, p=0.64 respectively). The time from the onset of MG and surgery, dosage and duration of pyridostegmine used preoperatively were not significantly different between the two groups (Table 1) (p=0.89, p=0.23, p=0.75). The time from atracurium administration to appearance of four responses of TOF were 48 min and 43 min in group A and group B respectively (Table 2). There was no significant difference between the two groups. Also the mean duration between induction and recovery phase was 45/5±11/9 minutes (25-65 minutes).

Discussion:

Myasthenia gravis is the prototype of antibody-mediated autoimmune disease. The acetylcholine receptor antibodies accelerated degeneration of the postsynaptic acetylcholine receptors of skeletal muscles and receptor blockade may also be involved (12). Anesthesia...
consideration in the MG patients include marked sensitivity to nondepolarizing muscle relaxants, and an increased risk of perioperative respiratory insufficiency requiring prolonged intubation. The unpredictable susceptibility to muscle relaxants in patients with MG requires special consideration for anesthetic management.

Table 1: Average Demographic and preoperative data

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group A (0.25 mg/Kg)</th>
<th>Group B (0.50 mg/Kg)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>28±3.2</td>
<td>32.4±2.8</td>
<td>0.36</td>
</tr>
<tr>
<td>Sex Ratio (M/F)</td>
<td>3/7</td>
<td>4/6</td>
<td>0.64</td>
</tr>
<tr>
<td>Duration of pyridostigmine used preoperatively (yr)</td>
<td>1.4±0.2</td>
<td>1.5±0.1</td>
<td>0.75</td>
</tr>
<tr>
<td>Dosage of pyridostigmine used preoperatively (mg)</td>
<td>282±32</td>
<td>240±26</td>
<td>0.23</td>
</tr>
<tr>
<td>Duration between the onset of Myasthenia Gravis and surgery (yr)</td>
<td>1.7±0.2</td>
<td>1.6±0.3</td>
<td>0.89</td>
</tr>
</tbody>
</table>

Table 2: Time to four responses of TOF

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group A (0.25 mg/Kg)</th>
<th>Group B (0.50 mg/Kg)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration between induction and recovery phase(minute)</td>
<td>48±3.2</td>
<td>43±4.4</td>
<td>0.24</td>
</tr>
</tbody>
</table>

Various case reports have focused on this problem and suggested several techniques for anesthesia in MG patients such as: reversal of neuromuscular blockad by sugammadex (13), laryngeal mask airway insertion with total intravenous anesthesia without muscle relaxant (14) use of cisatracurium (15), avoiding the use of muscle relaxant and dependence on propofol for tracheal intubation and maintenance of anesthesia (16), avoidance of muscle relaxant and induction of anesthesia with sevoflurane (17). On the other hand decreasing or avoidance of nondepolarizing muscle relaxant results in inadequate muscle relaxation for intubation and surgery in patients with myasthenia gravis under treatment by acetylcholinestrase. In our study despite the previous case reports, we found that the neuromuscular blockade duration is not significantly different between two dosages (0.25 mg/kg and 0.50 mg/kg) of atracurium for induction of the patients with MG undergoing thymectomy. We observed that the use of atracurium 0.25 mg/kg for airway control resulted in stable intraoperative
conditions and enabled muscle relaxation of patients with MG who had just undergone transsternal thymectomy. So it means that the beneficial effects of the half dose of atracurium is similar to standard dose.

**Conclusion:**
As the effects of nondepolarizing neuromuscular blockers are highly unpredictable and the distribution of muscle weakness is often uneven, we recommend use of low dose of atracurium in myasthenic patients to prevent profound muscle weakness and postoperative respiratory complications.

**Acknowledgements:**
The authors would like to thank vice chancellery of research, Mashhad University of Medical Sciences, Mashhad, Iran.

**Conflict of interests:**
The authors have no conflict of interests.

**References:**


15. Baraka A, Siddik S, Kawkabani N. Cisatracurium in a myasthenic patient
